

**AHNCI Neurologic Oncology Program Tumor Board**

Friday, February 28, 2020

12:00-1:00 p.m.

Jho Conference Room, 6th Floor, AGH

Join Zoom Meeting

<https://zoom.us/j/519670691>

Meeting ID: 519 670 691

Dial by your location

+1 646 558 8656

**Cases to be discussed**

|  |  |  |  |
| --- | --- | --- | --- |
| **Case** | **De-identified patient** | **Reason** | **Presenter** |
| 1 | RM MRN 1117544 | History of grade 3 anaplastic oligodendroglioma who underwent resection on February 19, 2018 by Dr. Aziz.  Rim enhancing mass at the L CP angle | AY |
| 2 | RC MRN 11175444 | History of astrocytoma/oligodendroglioma. MRI February 20, 2020 redemonstration of postop changes of left frontal craniotomy for left frontal mass resection.  No evidence of progression disease | TB |
| 3 | IH MRN 5557489 | History of juvenile pilocytic astrocytoma of hypothalamus with obstructive hydrocephalus on presentation in 2011 status post needle biopsy by Dr.Eng with subsequent radiation therapy in 2011 records not available and placement of a right-sided non programable shunt in 2011.  Patient only complains of minimal headaches, mild tinnitus and mild fatigue but works full-time.  Review MRI spectroscopy, perfusion study of brain questionable progression of disease verses radiation necrosis | TB |
| 4 | MN MRN: 10156721 | 57 y/o female with Primary CNS Lymphoma. Right brain biopsy completed on 11/18/2019 by Dr. Leonardo. Completed 6 cycles of R-MTX on 2/21/20. Planning to start treatment with high-dose Cytarabine. Presenting to review MRI Brain 2/20/20. | TR |
| 5 | CD MRN:  445189 | 54 y/o male with Left occipital Multinodular Glioblastoma, WHO Grade IV, MGMT unmethylated (0.05), IDH1 Wild-type, diagnosed 9/6/2019. S/p Temodar and concurrent XRT completed 11/22/2019. Currently on Avastin and Carmustine. Enhancement noted on MRI Brain 2/26/20. Presenting to review imaging. | TR |
| 6 | WH MRN:  976845 | 56 y/o male with  Left temporal Multifocal Glioblastoma, WHO Grade IV,  IDH WILD TYPE, MGMT Methylated (300.77),  diagnosed 5/17/2017. Presenting to review PET Brain 2/25/20. | TR |
| 7 | GM MRN:  3611244 | 46 y/o male with Left frontal Glioblastoma, WHO Grade IV, MGMT testing sample insufficient, IDH Wild type, diagnosed 11/11/2019. Patient on 2/15 was brought to AGH with concerns for hydrocephalus and requiring shunt adjustments. Presenting to discuss with neurosurgery | TR |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

AHN CME Credit

**TEXT 412-301-9919**save this number to your contacts–  
will use this **same** number every week to text your attendance

**Today’s SMS Code: ZAXNAP**

You must text within 24 hours of the start of tumor board. You will receive a text receipt and a link to confirm attendance and receive credit

Objectives: Upon completion of this activity, participants will have a better understanding of decision-making for complex Neurologic Oncology and be armed with clinical pathways to improve care.

Accreditation: Allegheny General Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement:Allegheny General Hospital designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)™*.  Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Disclosure: In accordance with the Accreditation Council for Continuing Medical Education (ACCME) and the policy of Allegheny General Hospital, presenters must disclose all relevant financial relationships, which in the context of their presentation(s), could be perceived as a real or apparent conflict of interest, (e.g., ownership of stock, honoraria or consulting fees). Any identifiable conflicts will be resolved prior to the activity. Any such relationships will be disclosed to the learner prior to the presentation(s).

Moderators and Presenters: Tulika Ranjan, MD and Stephen Karlovits, MD has nothing to disclose